A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LIXILAN JP-L
- Sponsors Sanofi
- 10 Aug 2017 Planned End Date changed from 22 Aug 2018 to 3 Oct 2018.
- 10 Aug 2017 Planned primary completion date changed from 22 Aug 2018 to 3 Oct 2018.
- 13 Jul 2017 Planned End Date changed from 1 Jul 2018 to 22 Aug 2018.